Microglial malfunction: the third rail in the development of Alzheimer's disease

Trends Neurosci. 2015 Oct;38(10):621-636. doi: 10.1016/j.tins.2015.08.006.

Abstract

Studies of Alzheimer's disease (AD) have predominantly focused on two major pathologies: amyloid-β (Aβ) and hyperphosphorylated tau. These misfolded proteins can accumulate asymptomatically in distinct regions over decades. However, significant Aβ accumulation can be seen in individuals who do not develop dementia, and tau pathology limited to the transentorhinal cortex, which can appear early in adulthood, is usually clinically silent. Thus, an interaction between these pathologies appears to be necessary to initiate and propel disease forward to widespread circuits. Recent multidisciplinary findings strongly suggest that the third factor required for disease progression is an aberrant microglial immune response. This response may initially be beneficial; however, a maladaptive microglial response eventually develops, fueling a feed-forward spread of tau and Aβ pathology.

Keywords: Alzheimer's disease; Aβ peptide; Braak stages; GWAS; epigenomics; microglia; tau phosphorylation; transcriptomics.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Alzheimer Disease / immunology*
  • Animals
  • Brain / immunology
  • Humans
  • Microglia / immunology*